Controlled-Release D-Mannose Granules for Prolonged Cystitis Relief
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current nutraceutical compositions for treating cystitis, particularly those containing D-mannose, suffer from poor patient compliance due to frequent dosing requirements and rapid excretion, leading to ineffective inhibition of bacterial adhesion and biofilm formation, and they do not maintain a prolonged high concentration in the urine.
Innovation Solution
A slow-release nutraceutical composition of D-mannose is developed, utilizing hydroxypropyl methylcellulose (HPMC) and/or hydroxyethylcellulose, along with plant oils and waxes, formulated as granules with a controlled release mechanism to inhibit bacterial adhesion and biofilm formation effectively.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If D-mannose is administered frequently to maintain high concentration in urine, then bacterial adhesion inhibition is improved, but patient compliance deteriorates due to frequent dosing requirements
Solution Approach 1:
The patent applies the dynamics principle by transitioning from static immediate-release tablets to dynamic controlled-release granules that adjust D-mannose release over time. The granules provide sustained release of D-mannose at controlled rates, maintaining therapeutic concentrations in urine without requiring frequent dosing, thus improving both reliability of bacterial adhesion inhibition and ease of operation through reduced dosing frequency
Solution Approach 2:
The patent applies preliminary action by pre-formulating D-mannose in controlled-release granule structures that automatically release the active ingredient over an extended period. This preliminary preparation of the release mechanism eliminates the need for frequent patient intervention, maintaining effective D-mannose levels throughout the dosing interval and improving compliance while ensuring reliable inhibition of bacterial adhesion
2Quantity of substance
If D-mannose is released rapidly, then initial concentration in urine is improved, but duration of action deteriorates due to rapid excretion
Solution Approach 1:
The patent applies periodic action through controlled-release granules that release D-mannose in a sustained, periodic manner over time. Instead of a single rapid release followed by excretion, the granules provide continuous periodic release of D-mannose, maintaining therapeutic concentrations in urine for extended periods and thereby extending the duration of action while preserving adequate concentration levels
Solution Approach 2:
The patent applies continuity of useful action by designing granules that continuously release D-mannose throughout the dosing interval. This continuous release mechanism ensures that therapeutic concentrations are maintained in urine without interruption, preventing the rapid decline seen with immediate-release formulations and thereby extending the duration of bacterial adhesion inhibition
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition achieves prolonged inhibition of bacterial adhesion to bladder walls, reducing cystitis relapses and recovery times by maintaining a progressive high concentration of D-mannose in the urine, thus enhancing treatment efficacy without frequent dosing.
Implementation Method 1
A slow-release nutraceutical composition of D-mannose is developed, utilizing hydroxypropyl methylcellulose (HPMC) and/or hydroxyethylcellulose, along with plant oils and waxes, formulated as granules with a controlled release mechanism
Implementation Method 2
The composition achieves prolonged inhibition of bacterial adhesion to bladder walls, reducing cystitis relapses and recovery times by maintaining a progressive high concentration of D-mannose in the urine
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to a nutraceutical composition comprising D-mannose, one or more colloids based on hydroxypropyl methylcellulose (HPMC) and optionally hydroxyethyl cellulose (HEC), one or more of a vegetable oil and a wax, optionally an alginate, particularly for use in maintaining the correct function of the urinary tract and as an adjuvant in treating cystitis.